Iron-binding antioxidant capacity is impaired in diabetes mellitus

Free Radical Biology and Medicine

Volumn 40, Issue 10, 2006, Pages 1749-1755

  Van Campenhout, Ann ^a   Van Campenhout, Christel ^b   Lagrou, Albert R ^a   Moorkens, Greta ^b   De Block, Christophe ^b   Manuel y Keenoy, Begoña ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Diabetes; Free radical; Iron; Lipid peroxidation; Transferrin

Indexed keywords

ALBUMIN; CERULOPLASMIN; HEMOGLOBIN A1C; IRON BINDING PROTEIN; TRANSFERRIN; TRANSFERRIN BINDING PROTEIN;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES CONTROL; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON METABOLISM; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; IRON; LIPID PEROXIDATION; MALE; MIDDLE AGED; TRANSFERRIN;

EID: 33646491002     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.01.010     Document Type: Article

References (23)

1. Kannel W., and McGee D. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 2 (1979) 120-126
2. Sies H. Oxidative stress: from basic research to clinical application. Am. J. Med. 91 (1991) 31S-38S
3. Griesmacher A., Kindhauser M., Andert S.E., Schreiner W., Toma C., Knoebl P., Pietschmann P., Prager R., Schnack C., and Schernthaner G. Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am. J. Med. 98 (1995) 469-475
4. Gallou G., Ruelland A., Campion L., Maugendre D., Le Moullec N., Legras B., Allannic H., and Cloarec L. Increase in thiobarbituric acid-reactive substances and vascular complications in type 2 diabetes mellitus. Diabete Metab. 20 (1994) 258-264
5. Gutteridge J.M., Rowley D.A., and Halliwell B. Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Detection of 'catalytic' iron and anti-oxidant activity in extracellular fluids. Biochem. J. 206 (1982) 605-609
6. Gutteridge J.M., and Quinlan G.J. Antioxidant protection against organic and inorganic oxygen radicals by normal human plasma: the important primary role for iron-binding and iron-oxidising proteins. Biochim. Biophys. Acta 1159 (1992) 248-254
7. Breuer W., Hershko C., and Cabantchik Z.I. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus. Sci. 23 (2000) 185-192
8. Van Campenhout A., Van Campenhout C.M., Lagrou A.R., and Manuel-y-Keenoy B. Transferrin modifications and lipid peroxidation: implications in diabetes mellitus. Free Radic. Res. 37 (2003) 1069-1077
9. Johnson R.N., Metcalf P.A., and Baker J.R. Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin. Chim. Acta 127 (1983) 87-95
10. Breuer W., and Cabantchik Z.I. A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal. Biochem. 299 (2001) 194-202
11. Gutteridge J.M. Antioxidant properties of the proteins caeruloplasmin, albumin and transferrin. A study of their activity in serum and synovial fluid from patients with rheumatoid arthritis. Biochim. Biophys. Acta 869 (1986) 119-127
12. Jarnum S., and Lassen N.A. Albumin and transferrin metabolism in infectious and toxic diseases. Scand. J. Clin. Lab. Invest. 13 (1961) 357-368
13. Telci A., Cakatay U., Kayali R., Erdogan C., Orhan Y., Sivas A., and Akcay T. Oxidative protein damage in plasma of type 2 diabetic patients. Horm. Metab. Res. 32 (2000) 40-43
14. Odonnell M.J., Martin P., Florkowski C.M., Toop M.J., Chapman C., Holder R., and Barnett A.H. Urinary transferrin excretion in type-1 (insulin-dependent) diabetes-mellitus. Diabet. Med. 8 (1991) 657-661
15. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care 26 Suppl. 1 (2003) S25-S27
16. Memisogullari R., and Bakan E. Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. J. Diabetes Complications 18 (2004) 193-197
17. Qian M., Liu M., and Eaton J.W. Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem. Biophys. Res. Commun. 250 (1998) 385-389
18. Sulieman M., Asleh R., Cabantchik Z.I., Breuer W., Aronson D., Suleiman A., Miller-Lotan R., Hammerman H., and Levy A.P. Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes. Diabetes Care 27 (2004) 2730-2732
19. Jacobs E.M., Hendriks J.C., van Tits B.L., Evans P.J., Breuer W., Liu D.Y., Jansen E.H., Jauhiainen K., Sturm B., Porter J.B., Scheiber-Mojdehkar B., von Bonsdorff L., Cabantchik Z.I., Hider R.C., and Swinkels D.W. Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Anal. Biochem. 341 (2005) 241-250
20. Gosriwatana I., Loreal O., Lu S., Brissot P., Porter J., and Hider R.C. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal. Biochem. 273 (1999) 212-220
21. Van Campenhout A., Van Campenhout C., Lagrou A.R., and Manuel-y-Keenoy B. Effects of in vitro glycation on Fe3+Binding and Fe3+isoforms of transferrin. Clin. Chem. 50 (2004) 1640-1649
22. Fernandez-Real J.M., Lopez-Bermejo A., and Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 51 (2002) 2348-2354
23. Van Campenhout, A.; Vab Camlpenhout, C.; Olyslager, Y. S.; Van Damme, O.; Lagrou, A. R.; Manuel-y-Keenoy, B. A novel method to quantify in vivo trasferrin glycation: applications in diabetes mellitus. Clinica Chimica Acta; in press.